Home / Market News / $AMGN
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Guggenheim Adjusts Price Target on Amgen to $435

Nov 5, 2026, 7:02 PM UTC · Primary ticker $AMGN

Guggenheim has increased its price target for Amgen to $435 from $378, while maintaining a Neutral rating. This adjustment implies a potential downside of 9.1% from Amgen's closing price on November 4, 2026, suggesting that despite the raised target, the stock may be considered overvalued by Guggenheim at its current market price.

Guggenheim, a financial firm, has updated its outlook on Amgen, raising its price target to $435. This is a positive signal in isolation, as a higher price target generally indicates increased confidence in the company's future performance. However, the firm maintained a 'Neutral' rating, and crucially, the new $435 target is still 9.1% below Amgen's closing price of $478.48 on November 4, 2026. This implies that Guggenheim believes Amgen's stock is currently trading above its fair value. For traders, this suggests a potential short-term downside risk for AMGN, as institutional sentiment, despite the raised target, indicates the stock may be overextended. Long-term investors might view the raised target as a positive sign for the company's fundamentals, but the immediate implication is a potential correction.

$AMGN negative Price target implies downside from current market price
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.